Freezing tumor plus two immunotherapies for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have melanoma that cannot be removed with surgery
- Your melanoma has grown after prior immune checkpoint therapy (like pembrolizumab or nivolumab or ipilimumab), and your doctor plans to start ipilimumab plus nivolumab
- You have a tumor spot that doctors believe can be frozen through the skin using imaging guidance
- You have measurable cancer outside the frozen area (so they can track response)
- You can safely receive immunotherapy based on general health tests (including limited steroid use and good blood counts/kidney/liver function)
- You must be able to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
This trial tests a combination of treatments for melanoma that has spread to the liver after standard treatment. It uses freezing (cryoablation), a targeted drug (lenvatinib), chemotherapy (dacarbazine), and two immunotherapy drugs to try to shrink liver tumors and control the cancer. The goal is to see if this combined approach is safe and effective for patients whose cancer has not responded to prior therapy.
This trial tests if freezing tumor cells (cryoablation) combined with two drugs (tislelizumab and lenvatinib) can help people whose solid tumors have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.